Known targets — ChEMBL curated mechanism
FAURPL10RPL10ARPL11RPL12RPL13RPL13ARPL14RPL15RPL17RPL18RPL18ARPL19RPL21RPL22RPL23RPL23ARPL24RPL26RPL27RPL27ARPL28RPL29RPL3RPL30RPL31RPL32RPL34RPL35RPL35ARPL36RPL36ARPL37RPL37ARPL38RPL39RPL4RPL41RPL5RPL6RPL7RPL7ARPL8RPL9RPL9P7RPL9P8RPL9P9RPLP0RPLP1RPS10RPS11RPS12RPS13RPS14RPS15RPS15ARPS16RPS17RPS18RPS19RPS2RPS20RPS21RPS23RPS24RPS25RPS26RPS27RPS27ARPS28RPS29RPS3RPS3ARPS4XRPS4Y1RPS5RPS6RPS7RPS8RPS9RPSA
The experimentally established mechanism targets of Cycloheximide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 1.00 |
| ▸ | EIF4A1 | P60842 | 1/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 1/20 | 1.00 |
| ▸ | FKBP14 | Q9NWM8 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cycloheximide SCHEMBL30020292 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL1714687 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL674135 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Naramycin B SCHEMBL29356383 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL1753509 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL24914327 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL26617 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL3764340 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL9344504 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA | |
| Cycloheximide SCHEMBL3764335 | 1.00 | FKBP1A (1.00) | FKBP1ASMN1; SMN2NR2F2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313225-A1 | Compositions Comprising a Triazole Compound | BASF SE (DE) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313225-A1 | Compositions Comprising a Triazole Compound | CYP1B1, CYP3A5, CYP4B1 | FKBP1A 3637/4885SMN1; SMN2 4500/4885NR2F2 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.